Severe hemolytic crisis after ceftriaxone administration.

Area of Science:

• Pharmacology
• Hematology
• Immunology

Background:

• Ceftriaxone is a widely used cephalosporin antibiotic.
• Hemolytic crisis is a serious adverse event associated with certain medications.
• Sickle cell disease (SCD) patients may have unique sensitivities to drug-induced hemolysis.

Observation:

• Two pediatric patients with sickle cell disease experienced severe hemolytic crisis.
• The onset of crisis occurred shortly after administration of ceftriaxone.
• Both patients were diagnosed with the presence of anticeftriaxone antibodies.

Findings:

• The presence of anticeftriaxone antibodies was confirmed in both pediatric SCD patients.
• These antibodies are strongly suspected to be the causative agent of the massive hemolysis.
• This suggests a potential immune-mediated mechanism linking ceftriaxone to hemolytic crisis in SCD.

Implications:

• Clinicians should be vigilant for hemolytic reactions in sickle cell disease patients receiving ceftriaxone.
• Testing for anticeftriaxone antibodies may be warranted in cases of unexplained hemolysis post-ceftriaxone exposure.
• This finding underscores the importance of understanding drug-specific immune responses in vulnerable patient populations.